Long-term follow-up after recanalisation of aortic arch atresia.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
05 Feb 2021
Historique:
pubmed: 27 6 2019
medline: 10 2 2021
entrez: 26 6 2019
Statut: epublish

Résumé

Aortic arch atresia (AAA) is one of the rarest obstructive defects. The presence of this anomaly in adult age is uncommon. The typical anatomic feature consists of a complete occlusion of the membranous obstruction resulting in an acquired atresia without flow continuity between the proximal and distal segments. This feature is important in determining the feasibility of percutaneous intervention. The aim of the present study was to share long-term follow-up data of adult patients with AAA requiring percutaneous interventions for the management of this rare anomaly involving five different centres. Retrospective data of 19 patients (12 males, 63.2%, mean age 32.2±18.9 years) diagnosed with AAA treated in five different centres between 1999 and 2017 were collected. All patients underwent percutaneous recanalisation by (1) radiofrequency (RF) system (five patients, 26.3%), (2) extra-stiff guidewire (12 patients, 63.2%), and (3) transseptal needle (two patients, 10.5%). All procedures were subsequently followed by covered stent implantation. Two patients developed complications during the procedure and one of them died. Over a median follow-up of 4.94 years, four (21%) patients were able to be weaned from medications for hypertension. All the patients underwent reassessment for recurrence or restenosis during the follow-up. Seven (36.8%) patients underwent successful stent dilatation with a balloon. After the intervention, one patient experienced a late complication; however, one patient died due to an unknown cause believed to be unrelated to the previous recanalisation procedure. Percutaneous treatment of AAA is feasible with good long-term survival. This study reports the largest case series so far available in the literature.

Identifiants

pubmed: 31235456
pii: EIJ-D-18-00857
doi: 10.4244/EIJ-D-18-00857
pmc: PMC9724876
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1274-e1280

Références

Ann Pediatr Cardiol. 2010 Jul;3(2):140-6
pubmed: 21234193
Eur Heart J. 1999 Jun;20(11):827-32
pubmed: 10329081
Br Heart J. 1970 Sep;32(5):633-40
pubmed: 5470045
Catheter Cardiovasc Interv. 2015 Nov 15;86(6):1063-7
pubmed: 26010462
Cardiol J. 2008;15(1):80-4
pubmed: 18651390
Rev Esp Cardiol (Engl Ed). 2016 Nov;69(11):1109-1111
pubmed: 27522278
Anadolu Kardiyol Derg. 2012 Feb;12(1):75-6
pubmed: 22231938
Pediatr Cardiol. 2005 Jul-Aug;26(4):431-9
pubmed: 15549617
Int J Cardiol. 2010 Apr 30;140(3):287-95
pubmed: 19100637
Cardiol Young. 2016 Jun;26(5):957-60
pubmed: 26346299
Pediatr Cardiol. 2008 Jan;29(1):207-9
pubmed: 17885781
Catheter Cardiovasc Interv. 2008 Nov 15;72(6):844-6
pubmed: 18798328
Catheter Cardiovasc Interv. 2011 Nov 15;78(6):933-9
pubmed: 21805575
Catheter Cardiovasc Interv. 2001 Aug;53(4):535-41
pubmed: 11515009
Catheter Cardiovasc Interv. 2007 Oct 1;70(4):569-77
pubmed: 17896405
Int J Clin Exp Med. 2014 Oct 15;7(10):3244-52
pubmed: 25419355
Congenit Heart Dis. 2012 Nov-Dec;7(6):E89-90
pubmed: 22494638
J Thorac Cardiovasc Surg. 2007 Sep;134(3):738-45
pubmed: 17723827

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH